β-Glucan, a 'specific' biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18)

Journal of Immunology

Volumn 163, Issue 6, 1999, Pages 3045-3052

  Yan, Jun ^a,d   Větvička, Václav ^a   Xia, Yu ^a   Coxon, Angela ^b   Carroll, Michael C ^c   Mayadas, Tanya N ^b   Ross, Gordon D ^a  

^a University of Louisville School of Medicine   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; CD11B ANTIGEN; CD18 ANTIGEN; COMPLEMENT COMPONENT C3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REJECTION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD18; ANTIGENS, NEOPLASM; BIOLOGICAL RESPONSE MODIFIERS; COMPLEMENT C3; COMPLEMENT C3B; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GLUCANS; IMMUNE SERA; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MACROPHAGE-1 ANTIGEN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; TUMOR CELLS, CULTURED; ZYMOSAN;

EID: 0345281592     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Diller, I. C., Z. T. Mankowski, and M. E. Fisher. 1963. The effect of yeast polysaccharides on mouse tumors. Cancer Res. 23:201.
2. Bohn, J. A., and J. N. BeMiller. 1995. (1→3)-β-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr. Polym. 28:3.
3. Chihara, G., Y. Maeda, J. Hamuro, T. Sasaki, and F. Fukuoka. 1969. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature 222:687.
4. Di Luzio, N. R., R. McNamee, E. Jones, J. A. Cook, and E. O. Hoffman. 1976. The employment of glucan and glucan activated macrophages in the enhancement of host resistance to malignancies in experimental animals. In The Macrophage in Neoplasia. M. A. Fink, ed. Academic Press, New York, p. 181.
5. Ohno, N., I. Suzuki, S. Oikawa, K. Sato, T. Miyazaki, and T. Yadomae. 1984. Antitumor activity and structural characterization of glucans extracted from cultured fruit bodies of Grifola frondosa. Chem. Pharm. Bull. 32:1142.
6. Seljelid, R. 1986. A water-soluble aminated β1-3-D-glucan derivative causes regression of solid tumors in mice. Biosci. Rep. 6:845.
7. Kitamura, S., T. Hori, K. Kurita, K. Takeo, C. Hara, W. Itoh, K. Tabata, A. Elgsaeter, and B. T. Stokke. 1994. An antitumor, branched (1→3)-β-D-glucan from a water extract of fruiting bodies of Cryptoporus volvatus. Carbohydr. Res. 263:111.
8. Wakui, A., M. Kasai, K. Konno, R. Abe, R. Kanamaru, K. Takahashi, Y. Nakai, Y. Yoshida, H. Koie, H. Masuda, et al. 1986. Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group. Jpn. J. Cancer Chemother. 13:1050.
9. Tanabe, H., N. Imai, and K. Takechi. 1990. Studies on usefulness of postoperative adjuvant chemotherapy with lentinan in patients with gastrointestinal cancer. J. Jpn. Soc. Cancer Ther. 25:1657.
10. Matsuoka, H., Y. Seo, H. Wakasugi, T. Saito, and H. Tomoda. 1997. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 17:2751.
11. Fujimoto, S. 1989. Clinical efficacies of schizophyltan (SPG) on advanced gastric cancer. Nippon Geka Gakkai Zasshi 90:1447.
12. Kimura, Y., H. Tojima, S. Fukase, and K. Takeda. 1994. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol. 511(Suppl.):192.
13. Nakano, T., K. Oka, K. Hanba, and S. Morita. 1996. Intratumoral administration of sizofiran activates Langerhans cell and T-cell infiltration in cervical cancer. Clin. Immunol. Immunopathol. 79:79.
14. Morikawa, K., R. Takeda, M. Yamazaki, and D. Mizuno. 1985. Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear β-1,3-D-glucan and other immunomodulators in murine cells. Cancer Res. 45:1496.
15. Scaringi, L., P. Marconi, M. Boccanera, L. Tissi, F. Bistoni, and A. Cassone. 1988. Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions. J. Gen. Microbiol. 134:1265.
16. Suzuki, M., T. Kikuchi, F. Takatsuki, and J. Hamuro. 1993. The role of tumor antigen specific delayed-type hypersensitivity responses in eradicating tumors by lentinan. Biotherapy 7:345.
17. Ross, G. D., V. Větvička, J. Yan, Y. Xia, and J. Větvičková. 1999. Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology 42:61.
18. Suzuki, M., T. Kikuchi, F. Takatsuki, and J. Hamuro. 1994. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells. Cancer Immunol. Immunother. 38:1.
19. 3) for β-glucans. Complement Inflamm. 4:61.
20. Thornton, B. P., V. Vǎtvička, M. Pitman, R. C. Goldman, and G. D. Ross. 1996. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1235.
21. Xia, Y., and G. D. Ross. 1999. Generation of recombinant fragments of CD11b expressing the functional β-glucan-binding lectin site of CR3 (CD11b/CD18). J. Immunol. 162:7285.
22. Větvička, V., B. P. Thornton, and G. D. Ross. 1996. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or NK cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98:50.
23. Fradin, C., T. Jouault, A. Mallet, J. M. Mallet, D. Camus, P. Sinaÿ, and D. Poulain. 1996. β-1,2-linked oligomannosides inhibit Candida albicans binding to murine macrophage. J. Leukocyte Biol. 60:81.
24. Forsyth, C. B., E. F. Plow, and L. Zhang. 1998. Interaction of the fungal pathogen Candida albicans with integrin CD11b/CD18: recognition by the I domain is modulated by the lectin-like domain and the CD18 subunit. J. Immunol. 161: 6198.
25. Xia, Y., V. Větvička, J. Yan, M. Hanikýřová, T. N. Mayadas, and G. D. Ross. 1999. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 162:2281.
26. Raychaudhuri, S., Y. Saeki, H. Fuji, and H. Kohler. 1986. Tumor-specific idio-type vaccines. I. Generation and characterization of internal image tumor antigen. J. Immunol. 137:1743.
27. Aida, Y., and M. J. Pabst. 1990. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J. Immunol. Methods 132:191.
28. Wessels, M. R., P. Butko, M. H. Ma, H. B. Warren, A. L. Lage, and M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92:11490.
29. Croix, D. A., J. M. Ahearn, A. M. Rosengard, S. H. Han, G. Kelsoe, M. H. Ma, and M. C. Carroll. 1996. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 183:1857.
30. 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 5:653.
31. Shevach, E. M. 1992. Immunofluorescence and cell sorting. In Current Protocols in Immunology. J. E. Colligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. Wiley and Sons, New York, p. 5.0.1.
32. Nakajima, H., S. Hashimoto, S. Nagao, Y. Kita, M. Khono, H. Ogawa, S. Abe, and D. Mizuno. 1984. Host-mediated antitumor effect of DMG, a degraded D-manno-D-glucan from Microellobosporia grisea culture fluid. Gann 75:253.
33. Větvička, V., B. P. Thornton, T. J. Wieman, and G. D. Ross. 1997. Targeting of NK cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J. Immunol. 159:599.
34. Old, L. J., D. A. Clarke, B. Benacerraf, and M. Goldsmith. 1960. The reticuloendothelial system and the neoplastic process. Ann. NY Acad. Sci. 88:264.
35. Ohno, N., K. Iino, T. Takeyama, I. Suzuki, K. Sato, S. Oikawa, T. Miyazaki, and T. Yadomae. 1985. Structural characterization and antitumor activity of the extracts from matted mycelium of cultured Grifola frondosa. Chem. Pharm. Bull. 33:3395.
36. Mizuno, T., T. Kinoshita, C. Zhuang, H. Ito, and Y. Mayuzumi. 1995. Antitumor-active heteroglycans from niohshimeji mushroom, Tricholoma giganteum. Biosci. Biotechnol. Biochem. 59:568.
37. Větvička, V., M. Hanikýřová, J. Větvičková, and G. D. Ross. 1999. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules. Clin. Exp. Immunol. 115:229.
38. Menard, S., M. I. Colnaghi, and P. G. Della. 1980. Comparison of the natural humoral antitumor reactivity of different strains of mice. Tumori 66:13.
39. Takahashi, K., M. Yamazaki, and S. Abe. 1988. Local induction of a tumor necrosis factor (TNF)-like cytotoxic factor in murine tissues with tumorous and nontumorous inflammation after systemic administration of antitumor polysaccharides. J. Pharmacobiodynamics 11:472.
40. Molina, H., V. M. Holers, B. Li, Y. F. Fang, S. Mariathasan, J. Goellner, J. Strauss-Schoenberger, R. W. Karr, and D. D. Chaplin. 1996. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 93:3357.
41. Zotter, S., and M. Muller. 1977. Natural antibody in mammary tumor virus-infected mice that reacts with intracytoplasmic A particles of mouse mammary tumors. J. Natl. Cancer Inst. 58:967.
42. Cote, R. J., D. M. Morrissey, A. N. Houghton, E. J. Beattie, Jr., H. F. Oettgen, and L. J. Old. 1983. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80:2026.
43. Disis, M. L., E. Calenoff, G. McLaughlin, A. E. Murphy, W. Chen, B. Groner, M. Jeschke, N. Lydon, E. McGlynn, R. B. Livingston, et al. 1994. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:16.
44. Seljelid, R., J. Bogwald, J. Hoffman, and O. Larm. 1984. A soluble β-1,3-D-glucan derivative potentiates the cytostatic and cytolytic capacity of mouse peritoneal macrophages in vitro. Immunopharmacology 7:69.
45. Sugawara, I., K. C. Lee, and M. Wong. 1984. Schizophyllan (SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells. I. Characteristics of SPG-treated macrophages. Cancer Immunol. Immunother. 16:137.
46. Sherwood, E. R., D. L. Williams, R. B. McNamee, E. L. Jones, I. W. Browder, and N. R. Di Luzio. 1987. In vitro tumoricidal activity of resting and glucan-activated Kupffer cells. J. Leukocyte Biol. 42:69.
47. Hirata, N., A. Tsuzuki, N. Ohno, M. Saita, Y. Adachi, and T. Yadomae. 1998. Cytokine synthesis of human monocytes stimulated by triple or single helical conformer of an antitumour (1→3)-β-D-glucan preparation, sonifilan. Zentralbl. Bakteriol. 288:403.
48. Marth, T., and B. L. Kelsall. 1997. Regulation of interleukin-12 by complement receptor 3 signaling. J. Exp. Med. 185:1987.
49. 2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 94:13140.
50. 2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest. 101:2720.